Type 2 diabetes mellitus - An autoimmune disease?

Nature Reviews Endocrinology

Volumn 9, Issue 12, 2013, Pages 750-755

  Velloso, Lício A ^a   Eizirik, Decio L ^b   Cnop, Miriam ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; OBESITY;

EID: 84888203171     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.131     Document Type: Review

References (67)

1. Danaei, G. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31-40 (2011).
2. Schulz, M. et al. Food groups as predictors for short-term weight changes in men and women of the EPIC-Potsdam cohort. J. Nutr. 132, 1335-1340 (2002). (Pubitemid 34606473)
3. Shoelson, S. E., Lee, J. & Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801 (2006). (Pubitemid 44033299)
4. Tsukumo, D. M. et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56, 1986-1998 (2007). (Pubitemid 47195825)
5. Ozcan, U. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461 (2004). (Pubitemid 39372439)
6. Milanski, M. et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J. Neurosci. 29, 359-370 (2009).
7. Pal, D. et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 18, 1279-1285 (2012).
8. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445 (2011).
9. Cnop, M., Foufelle, F. & Velloso, L. A. Endoplasmic reticulum stress, obesity and diabetes. Trends Mol. Med. 18, 59-68 (2012).
10. Eizirik, D. L., Miani, M. & Cardozo, A. K. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 56, 234-241 (2013).
11. Osborn, O. & Olefsky, J. M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18, 363-374 (2012).
12. Guarda, G. et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269-273 (2009).
13. Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939 (2009).
14. Winer, S. et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15, 921-929 (2009).
15. Witebsky, E., Rose, N. R., Terplan, K., Paine, J. R. & Egan, R. W. Chronic thyroiditis and autoimmunization. J. Am. Med. Assoc. 164, 1439-1447 (1957).
16. Ziegler, A. G. & Nepom, G. T. Prediction and pathogenesis in type 1 diabetes. Immunity 32, 468-478 (2010).
17. Yang, Y. & Santamaria, P. Lessons on autoimmune diabetes from animal models. Clin. Sci. (Lond.) 110, 627-639 (2006). (Pubitemid 43844732)
18. Roep, B. O. & Peakman, M. Diabetogenic T lymphocytes in human type 1 diabetes. Curr. Opin. Immunol. 23, 746-753 (2011).
19. von Herrath, M., Peakman, M. & Roep, B. Progress in immune-based therapies for type 1 diabetes. Clin. Exp. Immunol. 172, 186-202 (2013).
20. Eizirik, D. L., Colli, M. L. & Ortis, F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5, 219-226 (2009).
21. Winer, D. A. et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 17, 610-617 (2011).
22. Brooks-Worrell, B. M., Juneja, R., Minokadeh, A., Greenbaum, C. J. & Palmer, J. P. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 48, 983-988 (1999). (Pubitemid 29226343)
23. Barrett, J. C. et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41, 703-707 (2009).
24. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet. 42, 105-116 (2010).
25. Rafiq, S. et al. Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia 51, 2205-2213 (2008).
26. Winkler, C., Raab, J., Grallert, H. & Ziegler, A. G. Lack of association of type 2 diabetes susceptibility genotypes and body weight on the development of islet autoimmunity and type 1 diabetes. PLoS ONE 7, e35410 (2012).
27. Speliotes, E. K. et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42, 937-948 (2010).
28. Hempel, P. et al. Sera from patients with type 2 diabetes contain agonistic autoantibodies against G protein-coupled receptors. Scand. J. Immunol. 70, 159-160 (2009).
29. Zimering, M. B. & Pan, Z. Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. J. Clin. Endocrinol. Metab. 94, 2171-2177 (2009).
30. Fosgerau, K. et al. Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J. Endocrinol. 204, 265-273 (2010).
31. Wu, H. et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115, 1029-1038 (2007). (Pubitemid 46328297)
32. Corre, J. et al. Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors. J. Cell Physiol. 208, 282-288 (2006). (Pubitemid 43993418)
33. Rocha, V. Z. et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ. Res. 103, 467-476 (2008).
34. Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914-920 (2009).
35. Ilan, Y. et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc. Natl Acad. Sci. USA 107, 9765-9770 (2010).
36. Yang, H. et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J. Immunol. 185, 1836-1845 (2010).
37. Savic, S., Dickie, L. J., Wittmann, M. & McDermott, M. F. Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract. Res. Clin. Rheumatol. 26, 505-533 (2012).
38. Araujo, E. P. et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 148, 5991-5997 (2007). (Pubitemid 350146162)
39. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007). (Pubitemid 46588416)
40. Goldfine, A. B. et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346-357 (2010).
41. Tuncman, G. et al. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl Acad. Sci. USA 103, 10741-10746 (2006). (Pubitemid 44078046)
42. Perreault, M. & Marette, A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med. 7, 1138-1143 (2001). (Pubitemid 33010023)
43. Thaler, J. P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 122, 153-162 (2012).
44. Velloso, L. A. & Schwartz, M. W. Altered hypothalamic function in diet-induced obesity. Int. J. Obes (Lond.) 35, 1455-1465 (2011).
45. Milanski, M. et al. Inhibition of hypothalamic inflammation reverses diet-induced insulin resistance in the liver. Diabetes 61, 1455-1462 (2012).
46. Calegari, V. C. et al. Inflammation of the hypothalamus leads to defective pancreatic islet function. J. Biol. Chem. 286, 12870-12880 (2011).
47. Purkayastha, S., Zhang, G. & Cai, D. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-β and NF-κB. Nat. Med. 17, 883-887 (2011).
48. Calay, E. S. & Hotamisligil, G. S. Turning off the inflammatory, but not the metabolic, flames. Nat. Med. 19, 265-267 (2013).
49. Brooks-Worrell, B., Narla, R. & Palmer, J. P. Biomarkers and immune-modulating therapies for type 2 diabetes. Trends Immunol. 33, 546-553 (2012).
50. Barbarroja, N. et al. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS ONE 7, e48155 (2012).
51. Ehses, J. A. et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56, 2356-2370 (2007). (Pubitemid 47358243)
52. Richardson, S. J., Willcox, A., Bone, A. J., Foulis, A. K. & Morgan, N. G. Islet-associated macrophages in type 2 diabetes. Diabetologia 52, 1686-1688 (2009).
53. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
54. Igoillo-Esteve, M. et al. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by β cells in type 2 diabetes. Diabetologia 53, 1395-1405 (2010).
55. Mahdi, T. et al. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab. 16, 625-633 (2012).
56. Tuomi, T. et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42, 359-362 (1993). (Pubitemid 23045043)
57. Brooks-Worrell, B. & Palmer, J. P. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin. Exp. Immunol. 167, 40-46 (2012).
58. Cnop, M. et al. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 (Suppl. 2), S97-S107 (2005). (Pubitemid 43343337)
59. Reilly, S. M. et al. An inhibitor of the protein kinases TBK1 and IKK-e improves obesity-related metabolic dysfunctions in mice. Nat. Med. 19, 313-321 (2013).
60. Brassard, P. et al. Modulation of T-cell signalling by non-esterified fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 77, 337-343 (2007). (Pubitemid 350198860)
61. Beckman, E. M. et al. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 372, 691-694 (1994).
62. Cohen, N. R., Garg, S. & Brenner, M. B. Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv. Immunol. 102, 1-94 (2009).
63. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007). (Pubitemid 47025442)
64. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006). (Pubitemid 46018515)
65. Caricilli, A. M. et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol. 9, e1001212 (2011).
66. Geddes, K. et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat. Med. 17, 837-844 (2011).
67. Atarashi, K. & Honda, K. Microbiota in autoimmunity and tolerance. Curr. Opin. Immunol. 23, 761-768 (2011).